2018
DOI: 10.1016/j.scr.2018.03.019
|View full text |Cite
|
Sign up to set email alerts
|

Generation of induced pluripotent stem cells from a patient with Best Dystrophy carrying 11q12.3 (BEST1 (VMD2)) mutation

Abstract: Best disease (BD), also termed Best vitelliform macular dystrophy (BVMD), is a juvenile-onset form of macular degeneration and central visual loss. In this report, we generated an induced pluripotent stem cell (iPSC) line, TVGH-iPSC-012-04, from the peripheral blood mononuclear cells of a female patient with BD by using the Sendai virus delivery system. The resulting iPSCs retained the disease-causing DNA mutation, expressed pluripotent markers and could differentiate into three germ layers. We believe that BD… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 2 publications
0
1
0
Order By: Relevance
“…Induced pluripotent stem cell (iPSC) technologies have been shown to hold great promise for personalized therapy, translation medicine, and regeneration medicine [1]. Owing to the potential of iPSCs to be generated from somatic cells via the transduction of specific transcription factors [2], scientists reprogrammed patient-derived somatic cells to generate patient-specific iPSCs [3][4][5]. Remarkably, silencing the expression of human leukocyte antigen (HLA) class I allows to establish the universal human leukocyte antigen 2 of 18 (HLA) iPSCs characterized by low immunogenicity [6].…”
Section: Introductionmentioning
confidence: 99%
“…Induced pluripotent stem cell (iPSC) technologies have been shown to hold great promise for personalized therapy, translation medicine, and regeneration medicine [1]. Owing to the potential of iPSCs to be generated from somatic cells via the transduction of specific transcription factors [2], scientists reprogrammed patient-derived somatic cells to generate patient-specific iPSCs [3][4][5]. Remarkably, silencing the expression of human leukocyte antigen (HLA) class I allows to establish the universal human leukocyte antigen 2 of 18 (HLA) iPSCs characterized by low immunogenicity [6].…”
Section: Introductionmentioning
confidence: 99%